Type of chemotherapy has substantial effects on the immune system in ovarian cancer
Chemotherapy induces a variety of immunological changes. Studying these effects can reveal opportunities for successful combining chemotherapy and immunotherapy. Immuno-chemotherapeutic combinations in ovarian cancer are currently not generating the anticipated positive effects. To date, only scatte...
Main Authors: | Ann Vankerckhoven, Thaïs Baert, Matteo Riva, Christine De Bruyn, Gitte Thirion, Katja Vandenbrande, Jolien Ceusters, Ignace Vergote, An Coosemans |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523321000681 |
Similar Items
-
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
by: Thaïs Baert, et al.
Published: (2019-06-01) -
Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
by: Yanxiu Guo, et al.
Published: (2018-01-01) -
DIFFERENCES OF TUMOR MASSES AND HEMOGLOBIN LEVELS IN CERVICAL CANCER SQUAMOUS CELL TYPE PATIENTS TREATED WITH COMBINATION OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY
by: R. Noviyani, et al.
Published: (2014-01-01) -
Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma
by: R. Kawaguchi, et al.
Published: (2012-04-01) -
Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review
by: Shuji Ota, et al.
Published: (2019-01-01)